文献速递垂体与肾上腺疾病

嗜铬细胞瘤和副神经节瘤患者通用种系面板检测诊断率高

Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该研究回顾性分析了1727例疑似遗传性嗜铬细胞瘤和副神经节瘤(PPGL)患者的多种基因面板检测(MGPT)结果,发现27.5%携带致病或可能致病变异,9.0%为意义未明变异,63.1%为阴性。仅检测SDHB/C/D会漏检32.8%的致病变异携带者,数据支持对所有PPGL患者进行通用MGPT检测。

要点

  • 27.5%的疑似遗传性PPGL患者检出致病或可能致病变异。
  • SDHB变异占40.4%,为最常见基因,罕见基因合计贡献6.5%的致病变异。
  • 仅检测SDHB/C/D会漏检32.8%的致病变异携带者。

核心结论

  • 在具有和不具有已确立危险因素的个体中诊断率均较高,意义未明结果率低,罕见基因对诊断率有实质贡献。
  • 这些发现支持对所有PPGL个体进行通用检测,并使用同步MGPT作为理想平台。

研究设计与样本

  • 回顾性研究,纳入2013年8月至2019年12月期间因怀疑遗传性PPGL而接受靶向MGPT的1727例个体,数据来自美国商业实验室。

主要发现

  • 总体27.5%的个体携带致病或可能致病变异,9.0%为意义未明变异,63.1%为阴性结果。
  • 致病变异最常见于SDHB(40.4%),其次为SDHD(21.1%)、SDHA(10.1%)、VHL(7.8%)、SDHC(6.7%)、RET(3.7%)和MAX(3.6%)。
  • FH、MEN1、NF1、SDHAF2和TMEM127的致病变异合计占6.5%。
  • 致病变异的临床预测因素包括肾上腺外位置、发病年龄早、多发肿瘤和PPGL家族史阳性。
  • 肾上腺外副神经节瘤且家族史阳性的个体最可能携带致病变异(85.9%)。

关键数值与推荐

  • 仅检测SDHB/C/D会漏检32.8%的致病变异携带者。

临床怎么用

  • 作者认为这些发现支持对所有PPGL个体进行通用检测,并使用同步MGPT作为理想平台。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Practice guidelines to identify individuals with hereditary pheochromocytomas and paragangliomas (PPGLs) advocate for sequential gene testing strategy guided by specific clinical features and predate the routine use of multigene panel testing (MGPT). OBJECTIVE: To describe results of MGPT for hereditary PPGL in a clinically and ancestrally diverse cohort. SETTING: Commercial laboratory based in the United States. METHODS: Clinical data and test results were retrospectively reviewed in 1727 individuals who had targeted MGPT from August 2013 through December 2019 because of a suspicion of hereditary PPGL. RESULTS: Overall, 27.5% of individuals had a pathogenic or likely pathogenic variant (PV), 9.0% had a variant of uncertain significance, and 63.1% had a negative result. Most PVs were identified in SDHB (40.4%), followed by SDHD (21.1%), SDHA (10.1%), VHL (7.8%), SDHC (6.7%), RET (3.7%), and MAX (3.6%). PVs in FH, MEN1, NF1, SDHAF2, and TMEM127 collectively accounted for 6.5% of PVs. Clinical predictors of a PV included extra-adrenal location, early age of onset, multiple tumors, and positive family history of PPGL. Individuals with extra-adrenal PGL and a positive family history were the most likely to have a PV (85.9%). Restricting genetic testing to SDHB/C/D misses one-third (32.8%) of individuals with PVs. CONCLUSION: Our data demonstrate a high diagnostic yield in individuals with and without established risk factors, a low inconclusive result rate, and a substantial contribution to diagnostic yield from rare genes. These findings support universal testing of all individuals with PPGL and the use of concurrent MGPT as the ideal platform.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Horton C, LaDuca H, Deckman A, et al. Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield. J Clin Endocrinol Metab. 2022. PMID: 35026032. doi:10.1210/clinem/dgac014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。